Editor's ESMO 2016 roundup

PDL-1 assay concordance

Carcinoid syndrome

Who should receive combination therapy for ER positive breast cancer?

Drug repurposing of propranolol

Monitoring patterns of care in mCRPC patients with the help of the Cancer Registry

Highlights of ESMO 2016

Custirsen shows no survival benefit in metastatic prostate cancer

Cabozantinib over sunitinib for metastatic renal cell carcinoma

ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib

KRAS in the clinic and conference

A potential prognostic biomarker of chemoresistance in mCRC treated with FUFIRI or mIrOx (FIRE1)